

JAK3 (Phospho Tyr785) Rabbit pAb

Catalog#: AP0756 | Size: 30μL/50μL/100μL

Main Information

| Target | Host Species | Reactivity | Application | MW | Conjugated/Modification |
|--------|--------------|-------------------|--------------------|------------------|-------------------------|
| JAK | Rabbit | Human, Mouse, Rat | WB, IHC, IF, ELISA | 125kD (Observed) | Phospho |

Detailed Information

| Recommeded Dilution Ratio | WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000; IF 1:50-200 | |
|---------------------------|---|--|
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. | |
| Specificity | Phospho-JAK3 (Y785) Polyclonal Antibody detects endogenous levels of JAK3 protein only when phosphorylated at Y785. The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SDyEL | |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. | |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) | |
| Concentration | 1 mg/ml | |
| MW(Observed) | 125kD | |
| Modification | Phospho | |
| Clonality | Polyclonal | |
| Isotype | IgG | |



Antigen&Target Information

| Immunogen | The antiserum was produced against synthesized peptide derived from human JAK3 around the phosphorylation site of Tyr785. AA range:751-800 |
|--------------|--|
| Specificity | Phospho-JAK3 (Y785) Polyclonal Antibody detects endogenous levels of JAK3 protein only when phosphorylated at Y785. The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites): SDyEL |
| Gene Name | JAK3 |
| Protein Name | Tyrosine-protein kinase JAK3 |
| Other Name | JAK3 ;Tyrosine-protein kinase JAK3 ;Janus kinase 3 ;JAK-3 ;Leukocyte janus kinase ; L-JAK |

Database Link

| Organism | Gene ID | SwissProt |
|----------|---------|-----------|
| Human | 3718 | P52333 |
| Mouse | 16453 | Q62137 |
| Rat | | Q63272 |

Background

The protein encoded by this gene is a member of the Janus kinase (JAK) family of tyrosine kinases involved in cytokine receptor-mediated intracellular signal transduction. It is predominantly expressed in immune cells and transduces a signal in response to its activation via tyrosine phosphorylation by interleukin receptors. Mutations in this gene are associated with autosomal SCID (severe combined immunodeficiency disease). [provided by RefSeq, Jul 2008].

Function

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,Disease:Defects in JAK3 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-negative (T(-)B(+)NK(-)SCID) [MIM:600802]. SCID refers to a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients with SCID present in infancy with recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development., Domain: Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1., Function: Tyrosine kinase of the non-receptor type, involved in the interleukin-2 and interleukin-4 signaling pathway. Phosphorylates STAT6, IRS1, IRS2 and PI3K., online information: JAK3 mutation db, PTM: Tyrosine phosphorylated in response to IL-2 and IL-4., similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily, similarity:Contains 1 FERM domain.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 SH2 domain.,subcellular location:Wholly intracellular, possibly membrane associated., subunit: Interacts with STAM2 and MYO18A (By similarity). Interacts with SHB., tissue specificity. In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B- and M-forms are detected in cells both of hematopoietic and epithelial origins.



Cellular Localization

Endomembrane system; Peripheral membrane protein. Cytoplasm.

Tissue Expression

In NK cells and an NK-like cell line but not in resting T-cells or in other tissues. The S-form is more commonly seen in hematopoietic lines, whereas the B-form is detected in cells both of hematopoietic and epithelial origins.

Research Areas

- · Chemokine signaling pathway
- PI3K-Akt signaling pathway
- Necroptosis
- · Signaling pathways regulating pluripotency of stem cells
- JAK-STAT signaling pathway
- Th1 and Th2 cell differentiation
- Th17 cell differentiation
- Hepatitis B
- Measles
- · Human T-cell leukemia virus 1 infection
- · Epstein-Barr virus infection
- · Pathways in cancer
- · Viral carcinogenesis
- · Non-small cell lung cancer
- Primary immunodeficiency

Signaling Pathway

Cellular Processes >> Cell growth and death >> Necroptosis

Cellular Processes >> Cellular community - eukaryotes >> Signaling pathways regulating pluripotency of stem cells

Organismal Systems >> Immune system >> Th1 and Th2 cell differentiation

Organismal Systems >> Immune system >> Th17 cell differentiation

Organismal Systems >> Immune system >> Chemokine signaling pathway

Human Diseases >> Cancer: overview >> Pathways in cancer


Human Diseases >> Cancer: specific types >> Non-small cell lung cancer

Human Diseases >> Immune disease >> Primary immunodeficiency


Environmental Information Processing >> Signal transduction >> JAK-STAT signaling pathway

Environmental Information Processing >> Signal transduction >> PI3K-Akt signaling pathway

Validation Data




Western Blot analysis of 453 cells using Phospho-JAK3 (Y785) Polyclonal Antibody diluted at 1:1000




Western blot analysis of lysates from Jurkat cells, using JAK3 (Phospho-Tyr785) Antibody. The lane on the right is blocked with the phospho peptide.





Immunohistochemistry analysis of paraffin-embedded human brain, using JAK3 (Phospho-Tyr785) Antibody. The picture on the right is blocked with the phospho peptide.



Enzyme-Linked Immunosorbent Assay (Phospho-ELISA) for Immunogen Phosphopeptide (Phospho-left) and Non-Phosphopeptide (Phospho-right), using JAK3 (Phospho-Tyr785) Antibody

Contact Information

For Research Use Only. Not for Diagnostic Purposes